American Oncology Network Expands Access to Advanced Radioligand Therapies Across U.S. Network
American Oncology Network (AONC) announced the expansion of radioligand therapy (RLT) access across its network, with six community oncology practices now offering these advanced cancer treatments. The network has already administered over 300 treatments to nearly 70 patients across five partner practices.
The practices offer three FDA-approved radiopharmaceuticals: Pluvicto™ for metastatic castration-resistant prostate cancer, Lutathera® for gastroenteropancreatic neuroendocrine tumors, and Xofigo® for symptomatic mCRPC with bone metastases. RLT works by delivering targeted radiation directly to cancer cells while minimizing damage to healthy tissue.
American Oncology Network (AONC) ha annunciato l'espansione dell'accesso alla terapia radioligandica (RLT) all'interno della sua rete, con sei centri oncologici comunitari che ora offrono questi trattamenti oncologici avanzati. La rete ha già somministrato oltre 300 trattamenti a quasi 70 pazienti in cinque centri partner.
I centri propongono tre radiofarmaci approvati dalla FDA: Pluvicto™ per il carcinoma prostatico metastatico resistente alla castrazione, Lutathera® per i tumori neuroendocrini gastroenteropancreatici, e Xofigo® per mCRPC sintomatico con metastasi ossee. La RLT agisce erogando radiazioni mirate direttamente alle cellule tumorali, riducendo al minimo i danni ai tessuti sani.
American Oncology Network (AONC) anunció la expansión del acceso a la terapia con radioligandos (RLT) en toda su red, con seis clínicas oncológicas comunitarias que ahora ofrecen estos tratamientos avanzados contra el cáncer. La red ya ha administrado más de 300 tratamientos a casi 70 pacientes en cinco clínicas asociadas.
Las clínicas ofrecen tres radiofármacos aprobados por la FDA: Pluvicto™ para el cáncer de próstata metastásico resistente a la castración, Lutathera® para tumores neuroendocrinos gastroenteropancreáticos, y Xofigo® para mCRPC sintomático con metástasis óseas. La RLT funciona al administrar radiación dirigida directamente a las células cancerosas, minimizando el daño al tejido sano.
American Oncology Network (AONC)는 네트워크 전반에 걸쳐 방사성리간드 치료(RLT) 접근성을 확대했다고 발표했으며, 6개의 지역 종양학 진료소에서 이 첨단 암 치료를 제공하고 있습니다. 이 네트워크는 이미 5개 파트너 진료소에서 약 70명의 환자에게 300회 이상의 치료를 시행했습니다.
진료소에서는 FDA 승인 3가지 방사성 의약품을 제공합니다: 전이성 거세저항성 전립선암 치료용 Pluvicto™, 위장관 췌장 신경내분비종양용 Lutathera®, 그리고 골 전이가 있는 증상성 mCRPC용 Xofigo®. RLT는 암세포에 직접 표적 방사선을 전달하여 건강한 조직 손상을 최소화하는 방식으로 작용합니다.
American Oncology Network (AONC) a annoncé l'expansion de l'accès à la thérapie par radioligands (RLT) dans son réseau, avec six cabinets d'oncologie communautaires proposant désormais ces traitements avancés contre le cancer. Le réseau a déjà administré plus de 300 traitements à près de 70 patients dans cinq cabinets partenaires.
Les cabinets proposent trois radio-pharmaceutiques approuvés par la FDA : Pluvicto™ pour le cancer de la prostate métastatique résistant à la castration, Lutathera® pour les tumeurs neuroendocrines gastro-entéro-pancréatiques, et Xofigo® pour le mCRPC symptomatique avec métastases osseuses. La RLT agit en délivrant une radiation ciblée directement aux cellules cancéreuses tout en minimisant les dommages aux tissus sains.
Das American Oncology Network (AONC) hat die Erweiterung des Zugangs zur Radioligandentherapie (RLT) in seinem Netzwerk bekannt gegeben, wobei nun sechs onkologische Gemeinschaftspraxen diese fortschrittlichen Krebstherapien anbieten. Das Netzwerk hat bereits über 300 Behandlungen bei fast 70 Patienten in fünf Partnerpraxen durchgeführt.
Die Praxen bieten drei von der FDA zugelassene Radiopharmazeutika an: Pluvicto™ für metastasierten kastrationsresistenten Prostatakrebs, Lutathera® für gastroenteropankreatische neuroendokrine Tumoren und Xofigo® für symptomatisches mCRPC mit Knochenmetastasen. RLT wirkt, indem sie gezielte Strahlung direkt an Krebszellen abgibt und dabei Schäden am gesunden Gewebe minimiert.
- Successfully delivered over 300 treatments to nearly 70 patients, demonstrating strong adoption
- Expanded availability of advanced cancer treatments in community settings, reducing patient travel burden
- Offers all three FDA-approved radiopharmaceuticals for targeted cancer treatment
- Network positioned for continued growth as more sites gain infrastructure for these specialized treatments
- None.
Six AON community oncology practice partners now offering radioligand therapeutics for prostate and neuroendocrine cancers
FORT MYERS, Fla., May 21, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing community oncology networks, today announced it is expanding access to cutting-edge radioligand therapies (RLT), providing more patients with targeted treatment options for certain metastatic and rare cancers. To date, more than 300 treatments have been delivered to nearly 70 patients across five AON partner practices, demonstrating both the growing demand for and success of these advanced therapies.
Radioligand therapies are now offered at the following AON practices:
- Summit Cancer Centers
- Cancer & Blood Specialists of Arizona
- Woodlands Cancer Institute
- Messino Cancer Centers
- Zangmeister Cancer Center
- Genesis Cancer and Blood Institute
These practices offer three FDA-approved radiopharmaceuticals:
- Pluvicto™ – for treatment of metastatic castration-resistant prostate cancer (mCRPC)
- Lutathera® – for adults with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- Xofigo® (radium-223 dichloride) – for symptomatic mCRPC with bone metastases
“Radioligand therapy allows us to deliver highly targeted radiation directly to cancer cells, minimizing damage to healthy tissue and improving patient outcomes,” said Guy Messer, AON vice president of radiation and radiology services. “Our expansion of these therapies reflects AON’s continued commitment to ensuring that patients in community settings can access leading-edge treatments without having to travel far from home.”
Radioligand therapy, also know as radiopharmaceutical therapy, involves attaching a radioactive isotope to a targeting molecule that is injected into the bloodstream. This molecule binds to specific receptors on tumor cells, delivering a precise dose of radiation that damages or kills cancerous cells while sparing surrounding tissue.
Pluvicto™ is the first targeted radioligand therapy approved by the FDA to treat prostate-specific membrane antigen (PSMA)-positive mCRPC. Xofigo® is approved for men with mCRPC that has spread to the bone and who have already received androgen deprivation therapy. Lutathera® remains the only approved radiopharmaceutical for treating adult patients with GEP-NETs—a rare but increasingly diagnosed type of cancer that can develop in the pancreas, stomach, intestines or appendix.
“Continuing to increase the availability of these advanced radiopharmaceutical therapies in community oncology practices across the nation is a major step forward in personalized cancer care,” said Dr. Stephen “Fred” Divers, AON chief medical officer. “It’s part of AON’s broader mission to ensure patients nationwide have access to the latest innovations in oncology, without sacrificing the personalized care they receive close to home.”
AON expects continued growth in radioligand therapy utilization as additional sites gain the infrastructure and regulatory clearances needed to administer these specialized treatments.
About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 290 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/31ddea12-d6f2-4bf7-8cda-efb9e90eb230
Media Contact: Karen Riley Sawyer American Oncology Network Karen.Sawyer@AONcology.com
FAQ
What radioligand therapies does American Oncology Network (AONC) offer?
How many patients have received radioligand therapy through AONC?
How does radioligand therapy work in cancer treatment?
Which AONC practices offer radioligand therapy?
